RVMD News and Press, Revolution Medicines Inc. From 07/28/22

REDWOOD CITY, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the second quarter 2022 on Tuesday, Au...

Coinbase ( COIN ) powered further higher in Wednesday's midday trading. The stock was boosted by gains in the cryptocurrency market and by the firm's lack of exposure to some of the well-publicized recent crypto meltdowns. Earnings news remained a key catalyst as well. Omnicom ( N...

Gainers: Rhythm Pharmaceuticals ( RYTM ) +20% . Allakos ( ALLK ) +14% . Senti Biosciences ( SNTI ) +13% . Arcturus Therapeutics ( ARCT ) +7% . Verve Therapeutics ( VERV ) +5% . Losers: Vascular Biogenics ( VBLT ) -78%...

Vascular Biogenics ( VBLT ) -78% after late-stage trial for ovarian cancer treatment fails ; cut to Neutral at HC Wainwright after trial failure sinks stock 79%. Adial Pharmaceuticals ( ADIL ) -28% as AD04 fails to best placebo in very heavy drinkers in t...

Revolution Medicines ( NASDAQ: RVMD ) has priced an upsized $230M common stock offering at $20 per share. The underwritten public offering is for 115M shares. Underwriters have the opportunity to purchase an additional 1.725M shares. The offering is expected to clo...

REDWOOD CITY, Calif., July 19, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the pricing of its underwritten public offering of 11,500,000 shares of common stock a...

Revolution Medicines ( NASDAQ: RVMD ) on Tuesday has initiated plans to raise up to $200M in primary stock offering. The biotech company intends to grant the underwriters an overallotment option to purchase up to an additional $30M shares. J.P. Morgan, Cowen and G...

REDWOOD CITY, Calif., July 19, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that it has commenced an underwritten public offering to sell up to $200 million of sh...

REDWOOD CITY, Calif., July 13, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the appointment of Lorence Kim, M.D., to its board of directors. Dr. Kim has made sign...

Data on Amgen's Lumakras (sotorasib) in combination with Merck's ( NYSE: MRK ) Keytruda (pembrolizumab) and Roche's ( OTCQX:RHHBY ) Tecentriq (atezoliuzumab) will be released on Aug. 7 instead of this month, Reuters reported. Results will be released at the 20...